Menlo Therapeutics initiated at Cantor Fitzgerald

Cantor sees positive data driving Menlo shares higher, starts at Overweight. Cantor Fitzgerald analyst Louise Chen initiated coverage of Menlo Therapeutics with an Overweight rating and $25 price target. The analyst expects pipeline success to drive consensus earnings estimates and the stock higher. Chen believes a “positive, steady stream of pivotal data readouts” for Nularis, Tussix and Psorixa will begin in Q4 of this year.
https://thefly.com/landingPageNews.php?id=2786981